NUS vs USNA

For growth investors, USANA Health Sciences, Inc.

(USNA) is the stronger pick with 8. 3% revenue growth year-over-year, versus -14. 3% for Nu Skin Enterprises, Inc. (NUS). Nu Skin Enterprises, Inc. (NUS) offers the better valuation at 2. 3x trailing P/E (7. 3x forward), making it the more compelling value choice. Analysts rate Nu Skin Enterprises, Inc. (NUS) a "Hold" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Nu Skin Enterprises, Inc.

(NUS) is the cheapest at 2. 3x versus USANA Health Sciences, Inc. at 34. 5x. On forward P/E, Nu Skin Enterprises, Inc. is actually cheaper at 7. 3x.

Over the past 5 years, Nu Skin Enterprises, Inc.

(NUS) delivered a total return of -79. 2%, compared to -79. 7% for USANA Health Sciences, Inc. (USNA). Over 10 years, the gap is even starker: NUS returned -49. 1% versus USNA's -67. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), USANA Health Sciences, Inc.

(USNA) is the lower-risk stock at 1. 34β versus Nu Skin Enterprises, Inc. 's 1. 49β — meaning NUS is approximately 11% more volatile than USNA relative to the S&P 500. On balance sheet safety, USANA Health Sciences, Inc. (USNA) carries a lower debt/equity ratio of 2% versus 35% for Nu Skin Enterprises, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), USANA Health Sciences, Inc.

(USNA) is pulling ahead at 8. 3% versus -14. 3% for Nu Skin Enterprises, Inc. (NUS). On earnings-per-share growth, the picture is similar: Nu Skin Enterprises, Inc. grew EPS 207. 8% year-over-year, compared to -73. 5% for USANA Health Sciences, Inc.. Over a 3-year CAGR, USNA leads at -2. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nu Skin Enterprises, Inc.

(NUS) is the more profitable company, earning 10. 8% net margin versus 1. 2% for USANA Health Sciences, Inc. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: USNA leads at 5. 5% versus 4. 4% for NUS. At the gross margin level — before operating expenses — USNA leads at 78. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Nu Skin Enterprises, Inc.

(NUS) trades at 7. 3x forward P/E versus 11. 5x for USANA Health Sciences, Inc. — 4. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USNA: 74. 9% to $35. 00.

In this comparison, NUS (3.

2% yield) pays a dividend. USNA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Nu Skin Enterprises, Inc.

(NUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (3. 2% yield). Both have compounded well over 10 years (NUS: -49. 1%, USNA: -67. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Consumer Defensive sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NUS is a small-cap deep-value stock; USNA is a small-cap quality compounder stock. NUS pays a dividend while USNA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.